A critical region of loss of heterozygosity on human chromosome 13q14 harbors the tumor suppressor gene DICE1 (DDX26). To elucidate the reduced DICE1 expression in tumor cells, the putative promoter sequence upstream of the DICE1 gene was analysed. This sequence shows a high GC content and is rich in CpG sites and binding sites of transcriptional factors. Promoter activity was identified within three overlapping fragments of the 800 bp sequence upstream of the DICE1 gene. A 13 bp deletion polymorphism detected in the DICE1 promoter region showed a decreased activity compared with the undeleted variant. However, this 13 bp deletion was seen in male control samples and patients with prostate cancer or benign prostatic hyperplasia at similar rates. A reduced DICE1 expression was observed in prostate cancer cell lines DU145 and LNCaP. This downregulation is associated with hypermethylation of the DICE1 promoter. Treatment of both prostate cancer cell lines with 5-azacytidine leads to upregulation of DICE1 expression. Hypermethylation of CpG sites of the DICE1 promoter was observed in four of eight analysed prostate cancers. This study suggests that transcriptional repression of DICE1 is caused by hypermethylation of the DICE1 promoter region in prostate cancer cells.
Introduction
Prostate cancer is the most common cancer in the male population of the Western world. Chromosomal alterations have been associated with progression of prostate cancer and among structural aberrations deletions of the 13q14 region have been frequently identified by loss of heterozygosity (LOH) and comparative genomic hybridization (CGH) suggesting the presence of tumor suppressor genes in this critical region (Yin et al., 1999; Wolf et al., 2004) . Recently, the tumor suppressor gene DICE1 (DDX26; OMIM *604331) was identified to colocalize with the microsatellite marker D13S284 in 13q14.3. This chromosomal region is frequently affected by allelic deletions in prostate cancer and other solid tumors (Ueda et al., 1999; Yin et al., 1999; Wieland et al., 2001; Li et al., 2003) .
However, somatic mutations in the DICE1 gene were rarely detected in esophageal squamous cell carcinomas with LOH in 13q14.3 (Li et al., 2003) . Inactivation of tumor suppressor genes may also occur at the transcriptional level and is associated with aberrant methylation of normally unmethylated CpG islands in the promoter region (Klein, 2002) . Promoter methylation was observed in genes including RB1, p16, VHL, BRCA1, E-cadherin, APC, and FHIT in various human cancers (Serrano et al., 1996; Watanabe et al., 2001; Zo¨chbauer-Mu¨ller et al., 2001; Yang et al., 2002; Kuroki et al., 2003) .
Loss or downregulation of DICE1 expression was observed in primary tumors and cell lines of non-smallcell lung carcinomas and ectopic expression of the DICE1 gene was sufficient to suppress the ability for colony formation in human lung and prostate cancer cells (Wieland et al., , 2004 . Recently, two promoters and one enhancer were predicted by computational analysis upstream of the DICE1 transcriptional initiation site. In non-small-cell lung carcinoma, the reduced DICE1 expression was associated with hypermethylation in the putative promoter region of the DICE1 gene (Wieland et al., 2001) .
In this study, we analysed the DICE1 promoter and the effect of CpG hypermethylation on the promoter activity. We observed hypermethylation of the CpG sites in the DICE1 promoter in prostate cancer cells.
Results

Promoter activity of the 5
0 -flanking DICE1 region
Previously, a promoter region upstream of the DICE1 transcription start site was predicted by computer-based sequence analysis ( Figure 1a ; Wieland et al., 2001 ). This region was analysed for CpG islands. CpG islands were defined as regions larger than 200 bp, with an average GC content greater than 50% and a ratio of observed versus expected CpGs greater than 0.6 (GardinerGarden and Frommer, 1987) . These criteria revealed a CpG island of 681 bp with an average GC content of 70% and a ratio of observed versus expected CpGs of >0.8 ( Figure 1b ). This sequence of the putative DICE1 promoter was used to generate eight overlapping fragments that were analysed for promoter activity in COS-7 cells using a b-galactosidase reporter assay ( Figure 2a) . Three of the eight fragments exhibited promoter activity of at least 50% compared to the reference activity of the SV40 early promoter (Figure 2b ). The highest promoter activity was found in the DICE1Prom1 fragment comprising approximately 800 bp upstream of the transcription start site. Construct DICE1Prom6 possessed the basic promoter activity.
In the course of promoter analysis a 13 bp deletion was observed as part of a tandem repeat 618 bp upstream of the transcription start site of the DICE1 gene ( Figure 1a) . Analysis of this variant promoter fragment by the b-galactosidase reporter assay showed a 10.8% decreased promoter activity compared with the undeleted sequence in DICE1Prom1 fragment (Figure 2c ).
In vitro methylation with Sss I methylase of the DICE1Prom1 and DICE1Prom6 fragments resulted in a decrease of b-galactosidase activity of 96 and 100%, respectively ( Figure 2d ). To show that this decrease in b-galactosidase activity is mainly due to the methylated promoter sequence and not due to methylation of nonpromoter sequences, a control experiment with the SV40 early promoter was performed. Sss I methylation of the SV40 early promoter construct decreased b-galactosidase activity of only 20%. This demonstrates that methylation of non-promoter sequences does not severely interfere with the regulation of b-galactosidase expression.
We further analysed the basic promoter fragment DICE1Prom6 for the ability to bind proteins of HeLa nuclear extract that is enriched for transcription factors. In this assay a gel shift was observed upon incubation of radioactive labeled DICE1Prom6 with the HeLa nuclear extract (Figure 3 , lanes 1 and 2) whereas the unlabeled competitor reduced the labeled DICE1Prom6 protein interaction (Figure 3, lane 3) .
Frequency of the 13 bp deletion allele in patients with prostate cancer and control samples
To determine the frequency of the 13 bp deletion polymorphism in a normal population, lymphocyte Figure 1 The DICE1 promoter. (a) The sequence upstream of the DICE1 transcription initiation site ( þ 1) is shown with a black arrow. The predicted promoters are indicated with gray letters; the predicted promoter 1 is in italic letters. CpG sites are printed in bold letters. The tandem 13 bp repeat polymorphism is indicated by a box. (b) GC content of the predicted promoter region of the DICE1 gene (gray line) and the ratio of observed versus expected (obs versus exp) CpG sites (black line) were calculated as described (Gardiner-Garden and Frommer, 1987) CpG hypermethylation in the DICE1 promoter region A Röpke et al DNA from 264 unrelated probands (100 female and 164 male samples) was screened by PCR. Both cell lines were analysed for promoter methylation using the methylation-sensitive restriction enzymes AciI, AvaI, BsaHI, BssHII, BstUI, FnuH4I, HpaII, NaeI, NciI, PmlI, SacII, and CfoI. Altogether 21 CpG sites were analysed with methylation-sensitive restriction enzymes. The CpG sites screened are distributed over the 800 bp promoter fragment that exhibited the highest promoter activity in the b-galactosidase reporter assay. This analysis demonstrated a methylation of 10 of 11 analysed CpG sites in the 400 bp promoter fragment upstream of the transcription start site including the basic promoter and further 200 bp upstream corresponding to the DICE1Prom5 fragment (Figure 4 ). The only unmethylated CpG site was at the transcription initiation site. In contrast, no association between expression profile and methylation pattern in the prostate cancer cell lines and the normal prostate tissue was found in the DNA sequence 400-800 bp upstream of the transcription start site. The same results were obtained by the bisulfite method. PCR products amplified with primers specific for bisulfite modified DNA were used to investigate the methylation status of 16 CpG sites located between À134 and þ 77 bp, flanking the transcription initiation site of DICE1. The PCR products were cloned and single colonies were sequenced. In the normal prostate tissue no methylated CpG site was found. In the prostate cancer cell line LNCaP 10 of 16 analysed CpG sites were fully methylated and one additional CpG site was methylated in two of four analysed clones. In DU145 one clone showed no methylation, whereas all the other clones were methylated at 10 of 16 CpG sites ( Figure 5 ). CpG hypermethylation in the DICE1 promoter region A Röpke et al
Upregulation of DICE1 expression after treatment with 5-azacytidine
We investigated whether DICE1 mRNA was upregulated after 5-azacytidine treatment in the prostate cancer cell lines LNCaP and DU145 that showed reduced DICE1 expression. Expression of DICE1 mRNA measured by real-time PCR was upregulated in both cell lines after treatment for 4 days with 1.0 and 5.0 mM 5-azacytidine and for 10 days with 1.0 mM 5-azacytidine ( Figure 6 ). Treatment of both cell lines for 10 days with 5 mM 5-azacytidine was not possible due to cell death. DICE1 promoter methylation in prostate cancer samples Among 14 patients with prostate cancer 10 patients were found to be informative for microsatellite marker D13S284. Of these 10 informative patients, the tumor tissue of five samples demonstrated LOH. Among the five specimens without LOH, instability at D13S284 was detected in one sample.
After LOH analysis eight specimens including four samples with LOH, two without LOH and one noninformative sample as well as the case with microsatellite instability were selected to analyse the methylation status of the DICE1 promoter using bisulfite modified DNA. Methylated CpG sites were found in four of the eight analysed specimens. Among these four cases with methylated CpG sites there were two specimens with LOH, the case with microsatellite instability and one noninformative case ( Figure 5 ).
In the four specimens with LOH at D13S284 and DICE1 promoter methylation, tumor stages of pT3a (n ¼ 3) or pT3b (n ¼ 1) and Gleason scores of 6 (n ¼ 1), 7 (n ¼ 2) and 8 (n ¼ 1) were observed. The four unmethylated specimens comprise two cases with LOH and two cases without LOH. These unmethylated specimens demonstrated tumor stages of pT2a (n ¼ 1), pT2b (n ¼ 2) or pT3a (n ¼ 1) and Gleason scores of 5 (n ¼ 2) and 7 (n ¼ 2).
Discussion
Abnormal de novo methylation of CpG islands occurs frequently in a variety of human cancers including prostate cancer (Esteller and Herman, 2002) and hypermethylation of CpG sites is known to be associated with transcriptional inactivation (Bird, 2002) . In this study, we identified the promoter of the DICE1 gene and analysed the methylation pattern of the CpG sites in prostate cancer cell lines and prostate cancer samples. The DICE1 gene is localized in a critical region of LOH on human chromosome 13q14.3 (Wieland et al., , 2001 . LOH in the 13q14.3 region including the DICE1 gene was observed in approximately 30% of oral and prostate cancers and in about 70% of non-small-cell lung and esophageal squamous carcinomas (Tamura et al., 1997; Ogawara et al., 1998; Ueda et al., 1999; Yin et al., 1999; Li et al., 2003) . Recently, two promoters and one enhancer were predicted upstream of the transcriptional initiation site. We showed that in non-small-cell lung carcinomas expression of DICE1 is reduced apparently through promoter hypermethylation (Wieland et al., 2001) . Analysis of CpG islands revealed a 681 bp fragment including the promoter region predicted by computational analysis. In this fragment, an average GC content of 70% and a ratio of observed versus expected CpG sites of >0.8 was observed. These results fulfill the criteria of Gardiner-Garden and (1987) for CpG islands in vertebrate. To determine the promoter region of the DICE1 gene at a functional level the genomic sequence upstream of the transcriptional initiation site was analysed for promoter activity. Promoter deletion mutants linked to a bgalactosidase reporter identified an 800 bp sequence upstream of the transcriptional initiation site with optimal promoter activity. In contrast to the computational promoter search only a single basic promoter was found within a sequence of 250 bp upstream of the transcriptional initiation site. This basic promoter activity is reduced in a construct including the basic promoter sequence and the 5 0 -flanking 180 bp sequence suggesting some elements that may negatively influence transcription. The difference between the optimal and the basic promoter sequence (125.6 versus 82.8% relative activity in comparison to the SV40 early promoter) suggests that the sequence upstream of the basic promoter may include enhancer elements. Candidate enhancer elements could be the binding sites of the transcription factor ATF1 or CREB between 453 and 460 bp upstream of the transcriptional initiation site (Rehfuss et al., 1991) .
Sequence analysis of the DICE1 promoter led to the detection of a 13 bp deletion of the sequence À630 to À618 bp upstream of the DICE1 transcriptional initiation site. This polymorphism involves a CG-rich tandem repeat. The variant promoter sequence exhibited a 10.8% decreased promoter activity in COS-7 cells. Analysis of unrelated female or male individuals revealed no statistical difference in the frequency of the 13 bp deletion allele. Furthermore, there was also no statistical difference in the frequency of the 13 bp deletion allele in peripheral blood samples of healthy males or patients with prostate cancer or benign prostatic hyperplasia. Downregulation of gene expression is associated with either methylation of CpG islands in the promoter region or mutational inactivation (Klein, 2002; Strathdee, 2002) . In a recent study on esophageal squamous cell carcinomas somatic mutations were rarely detected in the DICE1 gene (Li et al., 2003) . In lung cancer, downregulation of the DICE1 gene is associated with methylation of CpG sites (Wieland et al., 2001) . Accordingly, in vitro methylation with Sss I methylase of the optimal and basic DICE1 promoter constructs resulted in loss of b-galactosidase activity whereas only a 20% decrease was observed for the SV40 early promoter construct. These results demonstrate that the significant decrease in promoter activity was due to in vitro methylation of CpG sites within the DICE1 promoter and not of CpG sites of the vector itself. Similar observations using in vitro methylated reporter constructs have been previously reported (Deng et al., 2001; DiNardo et al., 2001) . The gel shift assay revealed that the analysed DICE1 promoter fragment could bind proteins from the HeLa nuclear extract that is enriched with transcription factors. Obviously, transcription factors bind to the predicted promoter sequence, whereas methylated promoter sequences are not able to bind transcription factors (Ausubel, 1989; Jones and Baylin, 2002) . In both prostate cancer cell lines DU145 and LNCaP downregulated expression of DICE1 was found. The methylation pattern of these cell lines and normal prostate tissue was analysed at first by methylation-sensitive restriction enzymes. The cleavage regions are distributed over the whole optimal promoter (800 bp promoter fragment). A methylation pattern in correlation with the expression level was found in the first 400 bp upstream of the transcription initiation site. Both cell lines were methylated with the exception of the restriction enzyme cleavage site at the transcription initiation site. In contrast, the normal prostate tissue was unmethylated in eight of 11 cleavage sites. The other sites were partially methylated. In the promoter region 400-800 bp upstream of the transcription initiation site no correlation was found between normal prostate tissue expressing DICE1 and prostate cancer cell lines with downregulated DICE1 expression. Since the technique of methylation-sensitive restriction enzyme digestion is limited by the number of cleavage sites, sequencing of amplified bisulfite modified DNA was used to detect the methylation status of all CpG sites in the amplified sequence (Frommer et al., 1992) . Altogether 16 CpG sites, 13 upstream and three downstream of the transcription initiation site, were analysed. Using this method a negative correlation between expression level and methylation level was found. This analysis confirmed the results of the methylation-sensitive restriction enzyme digestion with the exception of the 4th analysed CpG site (PmlI cleavage site) at nucleotide position À117. These results demonstrate the significance of promoter methylation for inactivation of the DICE1 gene. This is further supported by the treatment of the cell lines with 5-azacytidine leading to upregulation of DICE1 expression. This agent reactivates the expression of genes if hypermethylation of CpG islands is the cause of gene silencing (Juttermann et al., 1994) .
Tumor DNA samples from 14 patients with prostate cancer were analysed for LOH at D13S284, a micro- Figure 6 Expression analysis of the DICE1 gene in prostate cancer cell lines treated with or without 5-azacytidine normalized to normal prostate tissue (100%). Cells were treated with 5-azacytidine over 4 (4d) and 10 days (10d), respectively. DICE1 expression was measured by real-time PCR. The relative DICE1 expression was calculated with the 2 ÀD(DCt) method (Livak and Schmittgen, 2001) satellite marker colocalizing with the DICE1 gene (Wieland et al., 2001) . Among the 10 informative specimens (at D13S284) LOH was detected in five cases. This is in good agreement with the study of Yin et al. (1999) . In this study, 61 prostate cancer samples were analysed and in 37.5% of informative cases LOH was found. This was the highest rate of LOH at chromosome 13. From the 14 tumor specimens eight DNA samples were selected and the methylation status was analysed. In four specimens methylated CpG sites were detected. One other sample exhibited a single partially methylated CpG site. The DICE1 promoter is obviously methylated in a subgroup of tumor cells of patients with prostate cancer. Both cases without LOH at D13S284 were unmethylated in contrast to the cases with LOH where two of four samples were methylated. Among the patients with methylated CpG sites in the DICE1 promoter only tumor stages of pT3a and pT3b and Gleason scores between six and eight were observed. This suggests that LOH at D13S284 is relevant for tumor progression.
In summary, we identified the promoter of the tumor suppressor gene DICE1 that is downregulated in prostate cancer cells. Our findings of hypermethylation of the DICE1 promoter in prostate cancer cell lines and primary prostate cancers suggest that hypermethylation of DICE1 may be involved in prostate cancer progression.
Materials and methods
Cell lines, tissue specimens, and study population Prostate cancer cell lines DU145 (Stone et al., 1978) and LNCaP (Gibas et al., 1984) and COS-7 cells (Gluzman, 1981) were propagated under standard cell culture conditions. Blood samples from females (n ¼ 100), males without diagnosis of prostate cancer (n ¼ 164), and patients with prostate cancer (n ¼ 37) or benign prostatic hyperplasia (n ¼ 13) were collected with approved consent.
Genotyping assay
For analysis of the 13 bp tandem repeat polymorphism in the DICE1 promoter genomic DNA from blood samples was amplified by standard PCR using Cy5-labeled forward primer 5 0 -AAAATCAGGTGGAAACAGAAT-3 0 and unlabeled reverse primer 5 0 -AAAGGCTAACATCGAAGGGA-3 0 . PCR products were analysed on an automatic sequencer (ALFexpress; Amersham Pharmacia Biotech).
Promoter analysis
Eight different PCR products were generated from genomic DNA to analyse the promoter activity of the 5 0 sequence of the DICE1 gene. PCR primers are listed in Table 1 . Hot-start PCR was performed with the HotStarTaq-Polymerase (Qiagen) in the presence of 1 Â Q-Solution (Qiagen). Conditions for PCR were as follows: 15 min at 951C, 35 cycles of 60 s at 951C, 60 s at specific annealing temperature (Table 1) and 60 s at 721C and finally 10 min at 721C. PCR products were analysed by agarose gel electrophoresis and the DNA was isolated from the gel with QIAEXII (Qiagen). The fragments were cloned into the pBlue-TOPO vector (Invitrogen) upstream of the Escherichia coli b-galactosidase gene (lacZ) and transformed into XL1-blue cells. As a reference the SV40 early promoter sequence was inserted into the pBlue-TOPO vector. Several colonies were analysed for correct orientation of the insert by sequencing. Plasmid DNA was isolated using the Plasmid Midi Kit (Qiagen). In vitro methylation with Sss I methylase (New England Biolabs) was performed on b-galactosidase reporter constructs DICE1Prom1, DICE1Prom6 and the SV40 early promoter as a control. Plasmid DNA (2 mg) was incubated with 5 U Sss I in buffer containing 50 mM NaCl, 10 mM TrisHCl (pH 7.9), 10 mM MgCl 2 , 1 mM dithiothreitol and 160 mM S-adenosylmethionine. S-adenosylmethionine was replenished after 5 h. The reaction was incubated at 371C overnight and DNA was ethanol precipitated. Plasmid DNA (1 mg) was transiently transfected into COS-7 cells (GeneJammer Transfection Reagent; Stratagene). After 2-3 days, cells were harvested as recommended and b-galactosidase activity was determined with the b-galactosidase reporter assay (Invitrogen). All transfections were repeated at least four times. The b-galactosidase acitivity of the cells transfected with the SV40 early promoter was set as 100%.
Electrophoretic gel shift assay
A PCR product was generated from genomic DNA with primers as described for DICE1Prom6 (Table 1) . A second PCR with the same primers was carried out using a[
32 P]-dCTP. For the protein-DNA interaction, the radioactive labeled DICE1Prom6 PCR product was incubated for 20 min with the HeLa nuclear extract (Gel Shift Assay Systems; Promega) as described by the manufacturer. In a parallel reaction, the unlabeled DICE1Prom6 was incubated with the protein DICE1Prom1  TCCAACTCCCACCTCTCGTG  GGGGCTGTTGGGGAGAAGTTTCAG  60  DICE1Prom2  TCCAACTCCCACCTCTCGTG  GCCTCTCCTTGGCTGTTGG  60  DICE1Prom3  TCCCCGGTCATAAACAACCTC  GTGGACAAACACCTGGTTAGGAG  59  DICE1Prom4  CACCTCCAACAGCCAAGGAG  ACCGCCTCGCCGTTCTAC  60  DICE1Prom5  CACCTCCAACAGCCAAGGAG  GGGGCTGTTGGGGAGAAGTTTCAG  60  DICE1Prom6  CTCTGCGCGTGCTCAATAAC  GGGGCTGTTGGGGAGAAGTTTCAG  59  DICE1Prom7  CTCTGCGCGTGCTCAATAAC  ACCGCCTCGCCGTTCTAC  59  DICE1Prom8  GGAGTGTGAGAGAGAAAAGC  GGGGCTGTTGGGGAGAAGTTTCAG  60  PCR4  CCTAACCAGGTGTTTGTCCAC  GCCTCTCCTTGGCTGTTGG  58  PCR5  CAGGAACCTCCTCCGGCG  GTGGACAAACACCTGGTTAGGAG  61  PCR6  TCCCCGGTCATAAACAACCTC  CGCCGGAGGAGGTTCCTG  59  PCR7  TCCAACTCCCACCTCTCGTG  GGAAGTGAGAGGTTGTTTATGAC  60 extract for 10 min, followed by the addition of the radioactive labeled PCR product. The reaction was stopped with loading buffer and separated on a 5% nondenaturing polyacrylamide/ bisacrylamide gel. The gel was dried under vacuum and exposed to an X-ray film for 72 h at À701C.
Promoter methylation assay
Methylation-sensitive restriction enzymes High molecular weight DNA (1 mg) from prostate cancer cell lines LNCaP and DU145 and normal prostate tissue was digested for 3 h with 10 U of methylation-sensitive restriction enzyme AciI, AvaI, BsaHI, BssHII, BstUI, FnuH4I, HpaII, NaeI, NciI, PmlI, SacII (New England Biolabs) or CfoI (Roche Diagnostics). Digested DNA was introduced into PCR as described (Wieland et al., 2001) . Four additional primer pairs were used for methylation analysis (Table 1 ; PCR 4-7). PCR products were separated and analysed by chemiluminescence as described (Wieland et al., 2001) . PCR products were hybridized with 5 0 and 3 0 DIG-labeled oligonucleotides (PCR4: 5 0 -CCTAACCAGGTGTTTGTCCAC-3 0 , PCR5: 5 0 -CGCCGG AGGAGGTTCCTGGGCCTC-3 0 , PCR6 and PCR7: 5 0 -GAG GGGAAGTGAGAGGTTGTTTATGACCGG-3 0 ). After hybridization, the PCR products of the digested DNA were compared with the undigested DNA. PCR products from the digested DNA with the proximate size of the undigested DNA were referred as hypermethylated at the analysed CpG site. PCR products with only a minor band in the digested DNA were referred as partially methylated. If no PCR product was observed the analysed CpG site was unmethylated.
Bisulfite modification and sequence analysis Sodium bisulfite modification of genomic DNA was performed using the CpGenome DNA Modifikation Kit (Intergen) as described by the manufacturer's recommendations. After modification, the PCR was performed using forward primer 5 0 -TTTAAA TATATGTTAATGAAAGGATAG-3 0 and reverse primer 5 0 -CCGATACAAAAATAAAAACCTAAAAAC-3 0 . PCR conditions were 5 min at 951C followed by 40 cycles of 60 s at 941C, 60 s at 561C, 60 s at 721C and finally 10 min at 721C. PCR products were separated on an 1.8% agarose gel and DNA was isolated using QIAEXII (Qiagen). The isolated DNA was cloned into the pGEM-Teasy vector (Promega) and transformed into XL1-blue cells. Up to 10 different clones were sequenced using the Auto Read Sequencing Kit (Amersham Pharmacia Biotech) on an automatic sequencer (ALFexpress; Amersham Pharmacia Biotech).
Expression of the DICE1 gene
Total RNA was extracted from prostate cancer cell lines LNCaP and DU145 and normal prostate tissue using the Trizol reagent according to the manufacturer's specifications (Invitrogen). For cDNA synthesis, 2 mg of total RNA was reverse transcribed as described (Wieland et al., 2001) . Realtime PCR was carried out using the DICE1 primers 5 0 -TGCCCATCTTACTGTTCCTG-3 0 and 5 0 -TCTTCGAAAGT GACCAGC-3 0 with the SYBR Green Supermix (Biorad) on the iCycler (Biorad). As reference the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was amplified using primers 5 0 -TGGTATCGTGGAAGGACT CA-3 0 and 5 0 -ATGCCAGTGAGCTTCCCGTT-3 0 . PCR conditions were described by Wieland et al. (1999) . The relative DICE1 expression in relation to the G3PDH expression was determined with the 2 ÀD(DCt) method as described by Livak and Schmittgen (2001).
5-Azacytidine treatment
For 5-azacytidine treatment, DU145 and LNCaP cells (1 Â 10 5 cells) were seeded in a 25 cm 2 culture flasks. After 24 h, cells were treated with and without 1 and 5 mM 5-azacytidine (Sigma Chemical), and the medium was changed after 24 h. After 4 and 10 days of treatment, cells were harvested for the analysis of DICE1 expression.
Tissue sample collection and LOH analysis
In total, 14 paired tumor and normal prostate tissue samples were obtained from 14 prostatectomy specimens. The tumor category was pT2a in three cases, pT2b in five cases, pT3a in five cases, pT3b in one case (Sobin and Wittekind, 1997). The Gleason score was 5 in three cases, 6 in two cases, 7 in eight cases and 8 in one case (Gleason et al., 1974) .
For LOH analysis tumor and corresponding normal tissue was microdissected and DNA was isolated using microdissection of membrane-based native tissue (MOMeNT) as described (Bo¨hm et al., 1997 . PCR was carried out to amplify microsatellite marker D13S284 (Dib et al., 1996) . The PCR product was diluted in 85% formamide buffer and separated on an ALFexpress sequencer (Amersham Pharmacia Biotech).
For bisulfite modification, DNA from eight tumor specimens was isolated from paraffin-embedded prostate cancer samples using the QIAamp DNA Mini Kit (Qiagen) as described by the manufacturer's instruction. After isolation, the DNA was eluted with 50 ml distilled H 2 O.
